Subscribe: Market Wire - Pharmaceuticals and Biotech: Drugs
http://img.marketwire.com/rss/mwPBDR.rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
announced  cancer  company  february  marketwired february  marketwired  neptune  offering  pieris  public offering  public  shares 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Drugs

Marketwired - Drugs



Marketwired - Drugs



Last Build Date: Fri, 16 Feb 2018 18:07:33 EST

Copyright: Copyright: (C) Marketwired
 



Pieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares

Fri, 16 Feb 2018 17:36:17 EST

BOSTON, MA--(Marketwired - February 16, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the closing of its previously announced underwritten public offering and the exercise in full of the underwriters' option to purchase additional shares. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Pieris, are $50.6 million. 6,325,000 shares of common stock at a public offering price of $8.00 per share were issued and sold in the offering, which includes 825,000 shares issued upon the exercise of the underwriters' option to purchase additional shares, less the underwriting discounts and commissions.




Moleculin Announces Pricing of $9 Million Registered Direct Offering

Fri, 16 Feb 2018 08:28:56 EST

HOUSTON, TX--(Marketwired - February 16, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it has entered into a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $9 million. The closing of the offering is expected to take place on or about February 21, 2018, subject to the satisfaction of customary closing conditions.




Thérapeutique Knight et SIFI S.p.A. annoncent le dépôt de présentation de drogue nouvelle de NETILDEX(MD) au Canada(TM)

Thu, 15 Feb 2018 08:46:34 EST

MONTRÉAL, QUÉBEC--(Marketwired - 15 fév. 2018) - Thérapeutique Knight inc. (TSX:GUD), (« Knight »), société pharmaceutique spécialisée et chef de file au Canada, et S.I.F.I- Società Industria Farmaceutica Italiana S.p.A. (« SIFI »), société italienne éminente dans le domaine des soins de la vue, ont annoncé aujourd'hui que la présentation de drogue nouvelle (PDN) par Knight de NETILDEXMD a été acceptée par Santé Canada. NETILDEXMD est une association médicamenteuse fixe de nétilmicine et de dexaméthasone destinée au traitement des troubles inflammatoires oculaires touchant le segment antérieur de l'oil, y compris les troubles postopératoires de cette nature, en présence d'une infection bactérienne ou d'un risque d'infection bactérienne.




Knight Therapeutics and SIFI S.p.A. Announce Filing of New Drug Submission for NETILDEX(TM) in Canada(TM)

Thu, 15 Feb 2018 08:45:04 EST

MONTREAL, QUEBEC--(Marketwired - Feb. 15, 2018) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, and S.I.F.I- Società Industria Farmaceutica Italiana S.p.A. ("SIFI"), a prominent Italian Eye Care company, today announced that Knight's New Drug Submission (NDS) for NETILDEXT has been accepted for review by Health Canada. NETILDEXT is a fixed combination of netilmicin and dexamethasone for the treatment of inflammatory ocular conditions of the anterior segment of the eye, including post-operative cases, where bacterial infection or a risk of bacterial infection exists.




Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment

Thu, 15 Feb 2018 08:30:00 EST

Cutting Edge Science Suggests New Molecule Is Capable of Shutting Down Tumor Activity




Solis Tek Announces Appointment of Co-Founder Alan Lien as Chief Executive Officer

Thu, 15 Feb 2018 08:30:00 EST

CARSON, CA--(Marketwired - February 15, 2018) - Solis Tek Inc. (OTCQB: SLTK), a vertically integrated technology innovator, developer, manufacturer and distributor focused on bringing products and solutions to commercial cannabis growers in legal markets across the U.S., today announced that its Co-Founder, Chairman, Chief Financial Officer and President, Alan Lien, has been appointed Chief Executive Officer. Mr. Lien replaces Dennis G. Forchic, who has been removed both from his role as CEO and as a member of the Board of Directors due to a difference in strategic outlook that was incompatible with the majority of the Founding Directors' plans and expectations for the Company.




Corbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model

Thu, 15 Feb 2018 07:00:00 EST

NORWOOD, MA--(Marketwired - February 15, 2018) -

  • Study identifies lenabasum as important upstream trigger of resolution of innate immune responses
  • Data provides mechanistic validation of positive clinical data reported from Company's Phase 2 clinical studies in systemic sclerosis, cystic fibrosis and dermatomyositis



Neptune annonce ses résultats pour le troisième trimestre

Wed, 14 Feb 2018 16:30:22 EST

Les activités du secteur du cannabis progressent comme prévu




Neptune Announces Third Quarter Results

Wed, 14 Feb 2018 16:00:00 EST

Cannabis Business Development Underway and On Schedule




Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference

Wed, 14 Feb 2018 07:00:00 EST

Live fireside chat presentation and webcast on Thursday, February 22 at 3:35 p.m. EST




Pieris Pharmaceuticals Announces Pricing of its Public Offering

Wed, 14 Feb 2018 00:27:18 EST

BOSTON, MA--(Marketwired - February 14, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the pricing of its previously announced underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $8.00 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Pieris, are expected to be $44.0 million. In addition, Pieris has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about February 16, 2018, subject to customary closing conditions.




Acasti Pharma Reports Third Quarter FY 2018 Financial Results

Tue, 13 Feb 2018 17:00:00 EST

Increased Cash Position Supports Initiation of CaPre Phase 3 Clinical Studies




Pieris Pharmaceuticals Announces Public Offering of Common Stock

Tue, 13 Feb 2018 16:01:00 EST

BOSTON, MA--(Marketwired - February 13, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Pieris intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering will be sold by Pieris.




Moleculin Announces Collaboration with Emory University to Develop Novel Treatment of Pediatric Brain Cancer

Tue, 13 Feb 2018 08:30:00 EST

HOUSTON, TX--(Marketwired - February 13, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has entered into an agreement with Emory University to enable expanded cancer research on Moleculin's WP1066 molecule for the possible treatment of medulloblastoma, a pediatric malignant primary brain tumor.




VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results

Mon, 12 Feb 2018 16:30:00 EST

SOUTH SAN FRANCISCO, CA--(Marketwired - February 12, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today reported financial results for its third fiscal quarter ended December 31, 2017.




Neptune et Tetra Bio-Pharma concluent une entente de codéveloppement de produits antidouleurs et anti-inflammatoires à base d'huiles de cannabinoïdes purifiés

Mon, 12 Feb 2018 12:43:09 EST

LAVAL, QUÉBEC--(Marketwired - 12 fév. 2018) - Neptune Technologies & Bioressources inc. (« Neptune ») (NASDAQ:NEPT)(TSX:NEPT) et Tetra Bio-Pharma Inc. (« Tetra ») (TSX CROISSANCE:TBP)(OTCQB:TBPMF) ont annoncé aujourd'hui la conclusion d'une entente de codéveloppement, de commercialisation et de mise en marché de produits à base d'huiles de cannabinoïdes purifiés contre la douleur et l'inflammation à l'intention des marchés des produits de santé naturelle et de la médecine vétérinaire.




Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation

Mon, 12 Feb 2018 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - Feb. 12, 2018) - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ:NEPT)(TSX:NEPT) and Tetra Bio-Pharma Inc. ("Tetra") (TSX VENTURE:TBP)(OTCQB:TBPMF) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets.




Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation

Mon, 12 Feb 2018 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - Feb. 12, 2018) - Tetra Bio-Pharma Inc. ("Tetra") (TSX VENTURE:TBP)(OTCQB:TBPMF) and Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ:NEPT)(TSX:NEPT) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets.